REVB Live signals | Maximize Profits with Getagraph.com

Live Chart Being Loaded With Signals

Commentary (26 Apr 2024 @ 16:00):

Revelation Biosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of immune system therapeutics and diagnostics...

Stats
Today's Volume	45 510.00
Average Volume	399 720
Market Cap	3.56M
EPS	$0 ( 2024-04-04 )
Next earnings date	( $-5.39 ) 2024-05-27
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-4.11
ATR14	$0.0330 (1.51%)

Insider Trading

Date	Person	Action	Amount	type
2023-12-08	Tidmarsh George F	Sell	27 771	Common Stock
2023-10-16	Tidmarsh George F	Sell	1 845	Common Stock
2023-10-16	Tidmarsh George F	Sell	10 957	Common Stock
2023-09-27	Chawla Lakhmir S	Buy	0
2023-09-28	Tidmarsh George F	Sell	1 429	Common Stock

INSIDER POWER
-12.44
Last 48 transactions
Buy: 316 523 \| Sell: 2 020 596

Volume Correlation

Long: 0.03 (neutral)

Short: 0.90 (strong)

Signal:(50.175) Same movement expected

Revelation Biosciences, Correlation

10 Most Positive Correlations
CNSL	0.915
EYE	0.915
AHCO	0.912
CCSI	0.905
DISH	0.879
COLB	0.878
ALHC	0.875
GBNH	0.872
CPTN	0.868
CSSE	0.864

10 Most Negative Correlations
KTCC	-0.913
JBSS	-0.895
RKDA	-0.883
HCDI	-0.882
HTBI	-0.874
WINT	-0.874
MBIN	-0.867
HUBG	-0.867
PESI	-0.861
WIRE	-0.859

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Revelation Biosciences, Correlation - Currency/Commodity

-0.69
( moderate negative )

-0.70
( moderate negative )

0.00
( neutral )

-0.70
( moderate negative )

0.74
( moderate )

0.61
( weak )

Revelation Biosciences, Financials

Annual	2023
Revenue:	$0
Gross Profit:	$-25 049.00 (0.00 %)
EPS:	$-0.530

FY	2023
Revenue:	$0
Gross Profit:	$-25 049.00 (0.00 %)
EPS:	$-0.530

FY	2022
Revenue:	$0
Gross Profit:	$-40 008.00 (0.00 %)
EPS:	$-600.77

FY	2021
Revenue:	$0.00
Gross Profit:	$0.00 (0.00 %)
EPS:	$-0.310

Financial Reports:

No articles found.

Revelation Biosciences,

Revelation Biosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of immune system therapeutics and diagnostics. The company engages in developing therapeutic product candidates, including REVTx-99b that is in a Phase Ib clinical trial for the prevention or treatment of chronic nasal congestion and allergic rhinitis; and REVTx-200, a nonclinical stage product for intranasal therapy. It is also involved in developing REVTx-300, a non-clinical stage product that is being developed as a potential therapy for the treatment of chronic organ disease, including chronic kidney disease and non-alcoholic steatohepatitis; and REVDx-501, a rapid test kit, which is a point of care in vitro diagnostic test that has the potential to detect respiratory viral infections, such as SARS-CoV-2, Influenza A, Influenza B, parainfluenza, or respiratory syncytial virus. The company was founded in 2020 and is based in San Diego, California.